相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials
Iris Noordhoek et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)
Eleftherios P. Mamounas et al.
CANCER RESEARCH (2020)
Comparative performance of Breast Cancer Index (BCIN+) and CTS5 in hormone receptor-positive (HR plus ) lymph node-positive (N plus ) breast cancer patients with one to three positive nodes (N1).
Dennis Sgroi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
J. M. S. Bartlett et al.
ANNALS OF ONCOLOGY (2019)
Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women
R. Gray
CANCER RESEARCH (2019)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer
Erik J. Blok et al.
EUROPEAN JOURNAL OF CANCER (2018)
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Lvana Sestak et al.
JAMA ONCOLOGY (2018)
Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
Elisabetta Munzone et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
Erik J. Blok et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
P. E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prediction of benefit from endocrine therapy in ER plus early stage breast cancer: Correlative studies of the breast cancer index HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2 expression in the randomized Stockholm trial
Yi Zhang et al.
CANCER RESEARCH (2015)
Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
Yi Zhang et al.
CLINICAL CANCER RESEARCH (2013)
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
Dennis C. Sgroi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Dennis C. Sgroi et al.
LANCET ONCOLOGY (2013)
Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer
Xiao-Jun Ma et al.
CLINICAL CANCER RESEARCH (2008)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Raimund Jakesz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The HOXB13:IL7BR expression index is a prognostic factor in early-stage breast cancer
Xiao-Jun Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
